{
    "title": "Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent",
    "pmid": "21505298",
    "pmcid": "PMC3387531",
    "study_parameters": [
        {
            "Study Parameters ID": 1185002093,
            "Variant Annotation ID": 1185002091,
            "Study Type": "case/control",
            "Study Cases": 52.0,
            "Study Controls": 173.0,
            "Characteristics": "Severe cutaneous toxicity - grade III or IV on NIAID Division of AIDS criteria.",
            "Characteristics Type": "Disease",
            "Frequency In Cases": 0.192,
            "Allele Of Frequency In Cases": "*35:01",
            "Frequency In Controls": 0.043,
            "Allele Of Frequency In Controls": "*35:01",
            "P Value": "= 0.022",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 5.65,
            "Confidence Interval Start": 2.03,
            "Confidence Interval Stop": 15.71,
            "Biogeographical Groups": "East Asian",
            "Variant Annotation ID_norm": "1185002091"
        },
        {
            "Study Parameters ID": 1185002085,
            "Variant Annotation ID": 1185002083,
            "Study Type": "case/control",
            "Study Cases": 57.0,
            "Study Controls": 277.0,
            "Characteristics": "Symptomatic grade >= 3 hepatic transaminase elevation (ALT or AST >5x ULN) or acute hepatic failure",
            "Characteristics Type": "Disease",
            "Frequency In Cases": 0.439,
            "Allele Of Frequency In Cases": "*01:01",
            "Frequency In Controls": 0.208,
            "Allele Of Frequency In Controls": "*01:01",
            "P Value": "= 0.0074",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 3.02,
            "Confidence Interval Start": 1.66,
            "Confidence Interval Stop": 5.49,
            "Biogeographical Groups": "Multiple groups, Caucasian and Hispanic/Latino patients",
            "Variant Annotation ID_norm": "1185002083"
        },
        {
            "Study Parameters ID": 1185002079,
            "Variant Annotation ID": 1185002071,
            "Study Type": "case/control",
            "Study Cases": 175.0,
            "Study Controls": 587.0,
            "Characteristics": "Severe cutaneous toxicity - grade III or IV on NIAID Division of AIDS criteria.",
            "Characteristics Type": "Disease",
            "Frequency In Cases": 0.377,
            "Allele Of Frequency In Cases": "*04:01",
            "Frequency In Controls": 0.194,
            "Allele Of Frequency In Controls": "*04:01",
            "P Value": "= 8.7E-6",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 2.51,
            "Confidence Interval Start": 1.73,
            "Confidence Interval Stop": 3.62,
            "Biogeographical Groups": "Multiple groups, Asian, Thai, Black, White",
            "Variant Annotation ID_norm": "1185002071"
        },
        {
            "Study Parameters ID": 1185002122,
            "Variant Annotation ID": 1185002120,
            "Study Type": "case/control",
            "Study Cases": 175.0,
            "Study Controls": 587.0,
            "Characteristics": "Severe cutaneous toxicity - grade III or IV on NIAID Division of AIDS criteria.",
            "Characteristics Type": "Disease",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.13",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 1.66,
            "Confidence Interval Start": 1.29,
            "Confidence Interval Stop": 2.15,
            "Biogeographical Groups": "Multiple groups, Asian, Black, White",
            "Variant Annotation ID_norm": "1185002120"
        },
        {
            "Study Parameters ID": 1185002101,
            "Variant Annotation ID": 1185002099,
            "Study Type": "case/control",
            "Study Cases": 175.0,
            "Study Controls": 587.0,
            "Characteristics": "Severe cutaneous toxicity - grade III or IV on NIAID Division of AIDS criteria.",
            "Characteristics Type": "Disease",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.019",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 1.76,
            "Confidence Interval Start": 1.36,
            "Confidence Interval Stop": 2.27,
            "Biogeographical Groups": "Multiple groups, Asian, Black, White",
            "Variant Annotation ID_norm": "1185002099"
        },
        {
            "Study Parameters ID": 1185002116,
            "Variant Annotation ID": 1185002114,
            "Study Type": "case/control",
            "Study Cases": 175.0,
            "Study Controls": 587.0,
            "Characteristics": "Severe cutaneous toxicity - grade III or IV on NIAID Division of AIDS criteria.",
            "Characteristics Type": "Disease",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.029",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 1.74,
            "Confidence Interval Start": 1.34,
            "Confidence Interval Stop": 2.25,
            "Biogeographical Groups": "Multiple groups, Asian, Black, White",
            "Variant Annotation ID_norm": "1185002114"
        }
    ],
    "var_drug_ann": [],
    "var_pheno_ann": [
        {
            "Variant Annotation ID": 1185002091,
            "Variant/Haplotypes": "HLA-B*35:01",
            "Gene": "HLA-B",
            "Drug(s)": "nevirapine",
            "PMID": 21505298,
            "Phenotype Category": "Toxicity",
            "Significance": "yes",
            "Notes": "The frequency of the HLA-B*35 allele was greater in those with nevirapine-related hepatic adverse events as compared to healthy controls when considering a Thai population. No significant results were seen for Asians (non-Thai), Blacks or Whites (p corrected = 0.053, 1.0, 1.0, respectively). Note that this annotation was done on HLA-B*35:01:01:01 because this was the first *35 allele discovered. p-value corrected for multiple testing.",
            "Sentence": "HLA-B *35:01 is associated with increased risk of Drug Toxicity when treated with nevirapine in people with HIV Infections.",
            "Alleles": "*35:01",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Drug Toxicity",
            "Multiple phenotypes And/or": "and",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV infectious disease",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "PMID_norm": "21505298",
            "Variant Annotation ID_norm": "1185002091"
        },
        {
            "Variant Annotation ID": 1185002083,
            "Variant/Haplotypes": "HLA-DRB1*01:01",
            "Gene": "HLA-DRB1",
            "Drug(s)": "nevirapine",
            "PMID": 21505298,
            "Phenotype Category": "Toxicity",
            "Significance": "yes",
            "Notes": "The frequency of the HLA-DRB1*01 allele was greater in those with nevirapine-related hepatic adverse events as compared to healthy controls when considering a White population. No significant results were seen for Asians or Blacks. Note that this annotation was done on HLA-DRB1*01:01:01 because this was the first *01 allele discovered. p-value corrected for multiple testing.",
            "Sentence": "HLA-DRB1 *01:01 is associated with increased risk of Drug Toxicity when treated with nevirapine in people with HIV Infections.",
            "Alleles": "*01:01",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Drug Toxicity",
            "Multiple phenotypes And/or": "and",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV infectious disease",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "PMID_norm": "21505298",
            "Variant Annotation ID_norm": "1185002083"
        },
        {
            "Variant Annotation ID": 1185002071,
            "Variant/Haplotypes": "HLA-C*04:01",
            "Gene": "HLA-C",
            "Drug(s)": "nevirapine",
            "PMID": 21505298,
            "Phenotype Category": "Toxicity",
            "Significance": "yes",
            "Notes": "The frequency of the HLA-Cw*04 allele was greater in those with nevirapine-related cutaneous adverse events as compared to healthy controls. Note that this annotation was done on HLA-C*04:01:01:01 because this was the first *04 allele discovered. p-value corrected for multiple testing.",
            "Sentence": "HLA-C *04:01 is associated with increased risk of Drug Toxicity when treated with nevirapine in people with HIV Infections.",
            "Alleles": "*04:01",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Drug Toxicity",
            "Multiple phenotypes And/or": "and",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV infectious disease",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "PMID_norm": "21505298",
            "Variant Annotation ID_norm": "1185002071"
        },
        {
            "Variant Annotation ID": 1185002120,
            "Variant/Haplotypes": "rs3745274",
            "Gene": "CYP2B6",
            "Drug(s)": "nevirapine",
            "PMID": 21505298,
            "Phenotype Category": "Toxicity",
            "Significance": "no",
            "Notes": "The frequency of the T allele was greater in those with nevirapine-related cutaneous adverse events as compared to healthy controls (p=5.5 x 10^-5). However, this association was not significant after correction for multiple testing. This SNP was in LD with rs3876547 and rs2054675 (r2 > 0.90). This SNP was not associated with hepatic adverse events after correcting for multiple comparisons.",
            "Sentence": "Allele T is associated with increased risk of Drug Toxicity when treated with nevirapine in people with HIV Infections.",
            "Alleles": "T",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Drug Toxicity",
            "Multiple phenotypes And/or": "and",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV infectious disease",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "PMID_norm": "21505298",
            "Variant Annotation ID_norm": "1185002120"
        },
        {
            "Variant Annotation ID": 1185002099,
            "Variant/Haplotypes": "rs2054675",
            "Gene": "CYP2B6",
            "Drug(s)": "nevirapine",
            "PMID": 21505298,
            "Phenotype Category": "Toxicity",
            "Significance": "yes",
            "Notes": "The frequency of the C allele was greater in those with nevirapine-related cutaneous adverse events as compared to healthy controls. This SNP was in LD with rs3876547 (r2 = 0.982) and rs3745274 (r2 > 0.90). p-value corrected for multiple testing. This SNP was not associated with hepatic adverse events after correcting for multiple comparisons.",
            "Sentence": "Allele C is associated with increased risk of Drug Toxicity when treated with nevirapine in people with HIV Infections.",
            "Alleles": "C",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Drug Toxicity",
            "Multiple phenotypes And/or": "and",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV infectious disease",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "PMID_norm": "21505298",
            "Variant Annotation ID_norm": "1185002099"
        },
        {
            "Variant Annotation ID": 1185002114,
            "Variant/Haplotypes": "rs3786547",
            "Gene": "CYP2B6",
            "Drug(s)": "nevirapine",
            "PMID": 21505298,
            "Phenotype Category": "Toxicity",
            "Significance": "yes",
            "Notes": "The frequency of the C allele was greater in those with nevirapine-related cutaneous adverse events as compared to healthy controls. This SNP was in LD with rs2054674 (r2 = 0.982) and rs3745274 (r2 > 0.90). p-value corrected for multiple testing. This SNP was not associated with hepatic adverse events after correcting for multiple comparisons.",
            "Sentence": "Allele C is associated with increased risk of Drug Toxicity when treated with nevirapine in people with HIV Infections.",
            "Alleles": "C",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "Side Effect:Drug Toxicity",
            "Multiple phenotypes And/or": "and",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:HIV infectious disease",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "PMID_norm": "21505298",
            "Variant Annotation ID_norm": "1185002114"
        }
    ],
    "var_fa_ann": []
}